ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates Posted byZacks Equity Research February 25, 2022 Leave a comment on ImmunoGen (IMGN) Reports Q4 Loss, Tops Revenue Estimates ImmunoGen (IMGN) delivered earnings and revenue surprises of 5.56% and 6.96%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?